Edward Reardon, DO
Rheumatology · Warwick, RINPI 1760488449
Payments from drug & device makers
Across 1,635 payments — averaging $246.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$87K
- Mallinckrodt Hospital Products Inc.$86K
- GSK$51K
- Amgen$47K
- Pfizer$42K
- UCB, Inc.$42K
- plus $47K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 267 | $87,151 |
| Mallinckrodt Hospital Products Inc. | 135 | $86,226 |
| GSK | 116 | $50,750 |
| Amgen(2 entities) | 300 | $46,993 |
| Pfizer | 144 | $42,440 |
| UCB, Inc. | 160 | $42,349 |
| Mallinckrodt Enterprises LLC | 17 | $18,759 |
| Novartis | 77 | $9,567 |
| Regeneron Healthcare Solutions, Inc. | 26 | $8,658 |
| Johnson & Johnson(2 entities) | 216 | $5,564 |
| Lilly USA, LLC | 24 | $673 |
| Sanofi | 4 | $629 |
| Hikma Pharmaceuticals USA | 23 | $389 |
| Genentech USA, Inc. | 23 | $388 |
| E.r. Squibb & Sons, L.L.C. | 19 | $354 |
| AstraZeneca | 16 | $282 |
| Bristol Myers Squibb | 10 | $270 |
| Fresenius Kabi USA, LLC | 12 | $213 |
| ANI Pharmaceuticals, Inc. | 8 | $206 |
| Medexus Pharma, Inc. | 11 | $144 |
| Boehringer Ingelheim | 5 | $126 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| Merck | 7 | $98 |
| Organon | 7 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Sobi, Inc | 1 | $17 |
How this compares
$402,556 in reported general payments places this provider in the 95th percentile of 22 rheumatology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Warwick
- Isha ShahWarwick$1K
- Jan KarczewskiWarwick$364
- Jay ToderJohnston$139K
- Deepan DalalCranston$122K
- Anthony ReginatoE. Providence$109K
- David KadmonLincoln$13K
- Christopher D ArcyWesterly$7K
- Jack MouradCranston$4K
- Vinit Joseph GilvazPawtucket$4K
- Wendy SilversmithWesterly$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.